Bionano Genomics (BNGO) Total Current Liabilities (2017 - 2026)

Bionano Genomics has disclosed Total Current Liabilities across 10 years of filings, most recently posting $21.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $21.2 million, down 19.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 million (down 19.62% YoY), and the FY2025 annual result was $22.9 million, down 38.57% from the prior year.
• Total Current Liabilities came in at $21.2 million for Q1 2026 at Bionano Genomics, down from $22.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $100.0 million in Q4 2023 to a low of $18.7 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $33.5 million (2023), against an average of $36.0 million.
• Across the five-year window, Total Current Liabilities surged 178.75% in 2023 and sank 62.67% in 2024, its largest moves.
• Bionano Genomics' Total Current Liabilities stood at $35.9 million in 2022, then soared by 178.75% to $100.0 million in 2023, then tumbled by 62.67% to $37.3 million in 2024, then plunged by 38.57% to $22.9 million in 2025, then retreated by 7.47% to $21.2 million in 2026.
• The last three Total Current Liabilities figures came in at $21.2 million (Q1 2026), $22.9 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.